Cancer Chemotherapy and Pharmacology

, Volume 24, Issue 3, pp 181–186

Potentiation of antimetabolite antitumor activity in vivo by dipyridamole and amphotericin B

  • Shou-song Cao
  • Yong-su Zhen
Original Articles Antitumor Activity, Dipyridamole, Amphotericin B

DOI: 10.1007/BF00300240

Cite this article as:
Cao, S. & Zhen, Y. Cancer Chemother. Pharmacol. (1989) 24: 181. doi:10.1007/BF00300240

Summary

Previous studies have shown that dipyridamole (DP), a potent nucleoside transport inhibitor blocking the rescue effect of exogenous nucleosides, markedly potentiates the cytotoxicity of antimetabolites. However, no enhancement of the chemotherapeutic effect of antimetabolites by DP in vivo has yet been reported. This study provided evidence that the combination of DP and amphotericin B (AmB) significantly potentiated the inhibitory effect of 5-fluorouracil (FU) or methotrexate (MTX) against a panel of transplantable tumors including sarcoma 180, cervical carcinoma U14, and Lewis lung carcinoma in mice. No significant increase in toxicity was induced by this combination in treated mice. Our results indicate that the combination of DP and AmB with antimetabolites is potentially useful in cancer chemotherapy.

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Shou-song Cao
    • 1
  • Yong-su Zhen
    • 1
  1. 1.Institute of Medicinal BiotechnologyChinese Academy of Medical SciencesBeijingChina